Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Pharmacodynamics, Pharmacokinetics, and Antiviral Activity of BAY 81-8781, a Novel NF-κB Inhibiting Anti-influenza Drug.

Droebner K, Haasbach E, Dudek SE, Scheuch G, Nocker K, Canisius S, Ehrhardt C, von Degenfeld G, Ludwig S, Planz O.

Front Microbiol. 2017 Nov 2;8:2130. doi: 10.3389/fmicb.2017.02130. eCollection 2017.

2.

The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus.

Haasbach E, Reiling SJ, Ehrhardt C, Droebner K, Rückle A, Hrincius ER, Leban J, Strobl S, Vitt D, Ludwig S, Planz O.

Antiviral Res. 2013 Sep;99(3):336-44. doi: 10.1016/j.antiviral.2013.06.008. Epub 2013 Jun 28.

PMID:
23811282
3.

Modification of the salivary secretion assay in F508del mice--the murine equivalent of the human sweat test.

Droebner K, Sandner P.

J Cyst Fibros. 2013 Dec;12(6):630-7. doi: 10.1016/j.jcf.2013.05.001. Epub 2013 Jun 13.

4.

Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo.

Droebner K, Pleschka S, Ludwig S, Planz O.

Antiviral Res. 2011 Nov;92(2):195-203. doi: 10.1016/j.antiviral.2011.08.002. Epub 2011 Aug 11.

PMID:
21854809
5.

Low-dose interferon Type I treatment is effective against H5N1 and swine-origin H1N1 influenza A viruses in vitro and in vivo.

Haasbach E, Droebner K, Vogel AB, Planz O.

J Interferon Cytokine Res. 2011 Jun;31(6):515-25. doi: 10.1089/jir.2010.0071. Epub 2011 Feb 16.

PMID:
21323570
6.

Influenza virus H5N1 hemagglutinin (HA) T-cell epitope conjugates: design, synthesis and immunogenicity.

Skarlas T, Zevgiti S, Droebner K, Panou-Pomonis E, Planz O, Sakarellos-Daitsiotis M.

J Pept Sci. 2011 Mar;17(3):226-32. doi: 10.1002/psc.1320. Epub 2010 Nov 30.

PMID:
21308879
7.

Highly pathogenic influenza virus infection of the thymus interferes with T lymphocyte development.

Vogel AB, Haasbach E, Reiling SJ, Droebner K, Klingel K, Planz O.

J Immunol. 2010 Oct 15;185(8):4824-34. doi: 10.4049/jimmunol.0903631. Epub 2010 Sep 22.

8.

The alternative NF-kappaB signalling pathway is a prerequisite for an appropriate immune response against lymphocytic choriomeningitis virus infection.

Droebner K, Klein B, Paxian S, Schmid R, Stitz L, Planz O.

Viral Immunol. 2010 Jun;23(3):295-308. doi: 10.1089/vim.2009.0101.

PMID:
20565293
9.

Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain.

Droebner K, Haasbach E, Fuchs C, Weinzierl AO, Stevanovic S, Büttner M, Planz O.

Vaccine. 2008 Dec 9;26(52):6965-74. doi: 10.1016/j.vaccine.2008.09.051. Epub 2008 Oct 9.

PMID:
18848593
10.

Role of hypercytokinemia in NF-kappaB p50-deficient mice after H5N1 influenza A virus infection.

Droebner K, Reiling SJ, Planz O.

J Virol. 2008 Nov;82(22):11461-6. doi: 10.1128/JVI.01071-08. Epub 2008 Sep 3.

11.

CYSTUS052, a polyphenol-rich plant extract, exerts anti-influenza virus activity in mice.

Droebner K, Ehrhardt C, Poetter A, Ludwig S, Planz O.

Antiviral Res. 2007 Oct;76(1):1-10. Epub 2007 May 15.

PMID:
17573133
12.

A polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance.

Ehrhardt C, Hrincius ER, Korte V, Mazur I, Droebner K, Poetter A, Dreschers S, Schmolke M, Planz O, Ludwig S.

Antiviral Res. 2007 Oct;76(1):38-47. Epub 2007 Jun 4.

PMID:
17572513

Supplemental Content

Loading ...
Support Center